Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masashi Kitano

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
International Journal of Molecular Sciences|January 14, 2017
Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate CancerHideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, et al.
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology|August 9, 2005
[Sudden death after 125I brachytherapy in prostate cancer patient: a case report]Masaki Kimura, Takefumi Satoh, Tetsuo Fujita, et al.
Oncology|March 14, 2008
Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vesselsTakahide Nakazawa, Shigeru Adachi, Masashi Kitano, et al.
Journal of Contemporary Brachytherapy|August 7, 2014
Catheter displacement prior to the delivery of high-dose-rate brachytherapy in the treatment of prostate cancer patientsShogo Kawakami, Hiromichi Ishiyama, Tsuyoshi Terazaki, et al.
World Journal of Radiology|January 12, 2016
Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapyHideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, et al.
International Journal of Radiation Oncology, Biology, Physics|June 14, 2011
Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trialHideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, et al.
Journal of Contemporary Brachytherapy|June 4, 2016
Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancerHideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, et al.
The Prostate|September 15, 2017
Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapyHideyasu Tsumura, Hiromichi Ishiyama, Ken-Ichi Tabata, et al.
Journal of Radiation Research|November 14, 2013
High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-upHiromichi Ishiyama, Takefumi Satoh, Masashi Kitano, et al.
Japanese Journal of Radiology|November 28, 2009
Cost comparison of curative therapies for localized prostate cancer in Japan: a single-institution experienceTakefumi Satoh, Hiromichi Ishiyama, Kazumasa Matsumoto, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
International Journal of Molecular Sciences|January 14, 2017
Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate CancerHideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, et al.
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology|August 9, 2005
[Sudden death after 125I brachytherapy in prostate cancer patient: a case report]Masaki Kimura, Takefumi Satoh, Tetsuo Fujita, et al.
Oncology|March 14, 2008
Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vesselsTakahide Nakazawa, Shigeru Adachi, Masashi Kitano, et al.
Journal of Contemporary Brachytherapy|August 7, 2014
Catheter displacement prior to the delivery of high-dose-rate brachytherapy in the treatment of prostate cancer patientsShogo Kawakami, Hiromichi Ishiyama, Tsuyoshi Terazaki, et al.
World Journal of Radiology|January 12, 2016
Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapyHideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, et al.
International Journal of Radiation Oncology, Biology, Physics|June 14, 2011
Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trialHideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, et al.
Journal of Contemporary Brachytherapy|June 4, 2016
Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancerHideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, et al.
The Prostate|September 15, 2017
Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapyHideyasu Tsumura, Hiromichi Ishiyama, Ken-Ichi Tabata, et al.
Journal of Radiation Research|November 14, 2013
High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-upHiromichi Ishiyama, Takefumi Satoh, Masashi Kitano, et al.
Japanese Journal of Radiology|November 28, 2009
Cost comparison of curative therapies for localized prostate cancer in Japan: a single-institution experienceTakefumi Satoh, Hiromichi Ishiyama, Kazumasa Matsumoto, et al.
Pageof 4